Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33(1 Suppl 2):S2–S5
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27(18 Suppl):(abstr 3)
O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A et al (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957
Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592
Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210–5217
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676
Sanchez-Munoz A, Perez-Ruiz E, Ribelles N, Marquez A, Alba E (2008) Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther 8(12):1907–1912
Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M et al (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A(4):527–531
Gennari A, Sormani M, Bruzzi P, Wilcken N, Nanni O, Fornier M, et al (2008) A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol 26(May 20 Suppl):abstr 1067
Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317(24):1490–1495
Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D et al (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer 39(5):614–621
Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A, et al. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. doi:10.1007/s10549-010-0860-9
Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. J Clin Oncol 22(13):2587–2593
Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24(24):3912–3918
Mayordomo J, Baena J, Cirera L, Sanchez-Rovira P, Godes M, Galan A et al (2009) Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. J Clin Oncol 27(15 suppl) (abstr 1001)
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an invited commentary to article doi: 10.1007/s10549-010-0860-9.
Rights and permissions
About this article
Cite this article
Murphy, C.G., Khasraw, M. & Seidman, A.D. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 122, 177–179 (2010). https://doi.org/10.1007/s10549-010-0925-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-0925-9